secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2026-08-13T20:31:12+00:00
Accession:  0001753926-26-001482
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Q2 net loss $6.4M; SLIM-1 fully enrolled; Novo Nordisk deal; Cortigent merger on track
--------------------------------------------------------------------------------

- Q2 2026 net loss $6.4M vs $7.1M in Q2 2025; cash $20.8M at June 30, 2026.
- SLIM-1 Phase 1 trial of NPM-139 fully enrolled (20 participants); top-line data expected November 2026.
- Non-exclusive agreement with Novo Nordisk to evaluate NPM-139 semaglutide implant; no exclusivity provisions.
- Cortigent merger with ClearOne expected to close Q3 2026; post-merger company to trade as CRGT on Nasdaq.
- August J. Moretti appointed to board; former CFO of 4D Molecular Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392626001482/0001753926-26-001482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392626001482/vani-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001753926-26-001482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer